Phaedra Chrousos - 22 May 2024 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Director
Signature
/s/ Phaedra Chrousos
Issuer symbol
VNDA
Transactions as of
22 May 2024
Net transactions value
$0
Form type
4
Filing time
24 May 2024, 16:43:11 UTC
Previous filing
12 Jun 2023
Next filing
09 Jun 2025
SEC
View on sec.gov

Key filing fact

Phaedra Chrousos filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 24 May 2024.

Key facts

  • This page summarizes Phaedra Chrousos's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 24 May 2024, 16:43.

Change

  • Previous filing in this sequence was filed on 12 Jun 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

VNDA transaction

Common Stock

Award

Transaction value
$0
Shares
+21,887
Change %
+52%
Price
$0.000000
Shares after
64,125
Date
22 May 2024
Ownership
Direct
Footnotes
F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

VNDA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+40,202
Change %
Price
$0.000000
Shares after
40,202
Date
22 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,202
Exercise price
$5.14
Footnotes
F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2 This option vests and becomes exercisable with respect to 100% of the option shares on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .